Dollars and Cents, Obesity and Sense

Let’s continue to explore the many ways in which our children, if allowed to become obese, could potentially be blamed and shamed by society. Those possibilities are all too likely. However, at least presently, they are not old enough to vote, and cannot yet be blamed for the measures that state and federal governments put into effect. We as adults, however, can be and are blamed by people who believe that the government should take no part in paying for people’s GLP-1 medications or anything of that sort.
Some critics with a specialized viewpoint do not believe that tax dollars should be used for that particular purpose, while others with different priorities would prefer to see those revenues utilized for purposes that they themselves can benefit from and exert control over. Such motivated citizens have strong opinions, like the anonymous social media critic who, early last year, claimed that “fat people are the costliest component of healthcare.”
Adjudicating that particular claim is better left to others. For our purposes today, it is enough to acknowledge that obesity as a national health problem already costs a lot of money and could grow even more. The notion that people who receive government assistance might get anti-obesity meds for free is repugnant to many Americans. They are totally against the idea that just for being overweight, without any life-threatening condition caused by that obesity, someone could qualify for special treatment.
The basic question concerns responsibility, which is just a softer word for the assignment of blame. But really, is obesity always and only the fault of an individual? What about genetics? What about environmental factors like “food deserts”? How about the inability to pay for good, nutritious food, even when it is available?
And what about the fact that parents are the ones who have the car and the money, and sole responsibility for deciding what a young family eats? Can children be assigned any blame at all when Mom and Dad buy, bring home, and prepare the food?
But shouldn’t motive be taken into account? So many parents are impoverished and unable to do anything meaningful for their children if there is a price tag. Can’t they be forgiven for buying cookies instead of carrots? It is huge, complicated, and in many respects an ugly problem.
Check in with experts
About a year and a half ago, Medical Economics published an article by Dr. Harith Rajagopalan, examining a situation that really has not changed much since then. It starts off with a bang:
Few public health issues have more devastating health consequences — or higher economic stakes — than today’s obesity epidemic… Without aggressive intervention, the number of people living with obesity or overweight [in America] is expected to rise to 260 million by 2050.
Already, he notes, almost three out of four adults in the U.S. are obese or overweight. And guess what proportion of the children? Around one in three.
No offense to the good doctor, but what if things are supposed to be this way? Couldn’t we just say, “Times change, populations change, things evolve, the world changes…” After all, the ancestors of humans didn’t used to walk upright, and yet we consider ourselves to be an improvement over them.
Maybe universal obesity is supposed to be where everything is heading, for evolutionary reasons that we do not yet understand. Maybe obese humans will turn out to be better able to withstand extreme climate change and ever-increasing pollution.
Okay, let’s get serious. When the people in Washington first posited, then ditched the idea of having Medicare and Medicaid pay for people’s GLP-1 drugs, plenty of constituents on both sides were angry for opposite reasons. But one of the problems is that two years in, only one out of every four patients still adheres to the weight-loss drug regimen — and not because they don’t need it.
Please consult the article for the fancy math involved, but the bottom line presented here is:
Unfortunately, the reality is that adherence rates are low. Without ongoing treatment, patients are back to square one: all therapeutic benefit and financial investment evaporate.
Dr. Rajagopalan lays out some of the cold, hard facts of the case:
[S]tandard GLP-1 therapy costs about $550 per month, but after two years, only one in four patients remains on the drug. This means for every 100 patients starting therapy, the total cost over two years reaches $845,625. When divided by the 25 patients who are actually adherent and continue treatment, the true cost per long-term user soars to $33,825…
[T]he total cost to prevent just ONE cardiovascular event based on the results of the trial exceeds $2.2 million.
Of course, no price should ever be set on any human life. But there it is, one of the as-yet-insoluble dilemmas of the case.
Your responses and feedback are welcome!
Source: “Obesity’s $250 billion problem,” MedicalEconomics.com, 04/16/25
Image by biker_becca/Pixabay









FAQs and Media Requests: